The BioInsights Podcast

From one target to many: how high‑plex ddPCR is changing CGT from development to analytics 24.06.2026 15min

Lauren Coyle, Editor, BioInsights, speaks with Christian Overgaard, Senior Field Application Scientist, Bio‑Rad Laboratories, about the technical and practical evolution of droplet digital PCR (ddPCR) and high‑plex multiplexing, covering assay design challenges, vector integration analysis, biodistribution studies, and the emerging role of digital PCR in cell and gene therapy characterization and clinical development.

Beyond one and done: engineering durable, redosable cell‑based gene therapies 17.06.2026 18min

The one‑and‑done model has defined gene therapy for a generation. Chris Hopkins thinks it is time to move on. At ASGCT 2026, Abi Pinchbeck spoke with the Co‑founder and CEO of Glafabra Therapeutics on redoseable cell‑based gene therapy, a platform spanning Fabry, Pompe, and Gaucher diseases, and what durable, if not permanent, treatment could mean for patients. A podcast version of this discussion is also available.

Precision by design: engineering site‑specific ADCs with machine learning 21.05.2026 24min

Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Weston Kightlinger, CEO, Ridge Bio, about the challenge of DAR heterogeneity and site specificity in ADC development, Ridge Bio’s ML‑driven enzyme and linker engineering platforms, and what site‑specific conjugation means for the future of ADCs as the field moves beyond oncology.

Crossing the ADC inflection points: what separates clinical success from failure 23.02.2026 30min

Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Antoine Yver, Board Chair, Ona Therapeutics, with more than three and a half decades of experience shaping global cancer drug development. In this conversation, they explore what determines whether an ADC successfully crosses the critical threshold and how teams should rethink dose finding, toxicity, and what it truly takes to set a program up for long-term success in the clinic.

Formulation and delivery of RNA-based vaccines and therapeutics: addressing outstanding questions around safety and purity 06.11.2025 24min

In this interview, Róisin McGuigan, Editor, Nucleic Acid Insights, and Jesse Erasmus, Director of Virology at HDT Bio, discuss current challenges and opportunities in RNA safety, manufacturing, and targeted delivery, and the key ongoing obstacles facing viral and LNP-based delivery modalities.

Advancing nucleic acid therapeutics with circular RNA 27.10.2025 33min

In this podcast episode, Jokūbas Leikauskas, Editor, BioInsights, speaks to Trevor Hallam, who served as Chief Scientific Officer of Sail Biomedicines until July 2025. The interview, recorded in June 2025, explores advances in RNA therapeutics, particularly circular RNA (circRNA or eRNA) technologies, and how they may help overcome current limitations in delivery, durability, and specificity for applications such as CAR-T cell therapies and autoimmune disease treatment.

Exploring advances in bioconjugation: nanozymes, tissue tropism, and the future of responsive systems 01.10.2025 15min

Lauren Coyle (Commissioning Editor, Bioconjugation Insights) speaks to Vincent Rotello (Distinguished Professor of Chemistry, University of Massachusetts Amherst) about the advantages and limitations of different nanomaterial platforms, and emerging strategies such as tissue tropism and responsive nanozymes that could advance targeted therapeutic and diagnostic delivery.

The promise of antibody-oligonucleotide conjugates for neurological diseases 27.08.2025 21min

Lauren Coyle, Launch Commissioning Editor, Bioconjugation Insights, speaks with Kerstin Hofer, Science and People Lead, Roche, about the evolving application of antibody-oligonucleotide conjugates in neurology. She highlights their design, delivery challenges across the blood–brain barrier, and potential to transform CNS diseases.

From innovation to access: bridging gaps in scalability and cold chain precision logistics for advanced therapies 18.07.2025 19min

Jokūbas Leikauskas, Editor, BioInsights, speaks to Rohin Iyer, Senior Director, Global Cell and Gene Therapy Operations, Marken, about addressing the complex logistics of cell and gene therapies through global infrastructure, precision, and advanced technologies. They also discuss evolving cold chain needs, regulatory and geopolitical challenges, and the need for scalability.

Enhancing mRNA results through strategic RNA design and quality control 27.03.2025 12min

In the last few years, mRNA has moved to the fore in the vaccine and cell and gene therapy fields, and as a result, its successful production for these downstream applications has never been more crucial. In this podcast episode, Róisin McGuigan, Editor, Nucleic Acid Insights, speaks to Ryan Lahr, Senior R&D Scientist, CELLSCRIPT, about design, production, and quality control of synthesized mRNA for translation in cells.

For the many and the few: bringing ASO therapies to both mainstream and nano-rare indications 13.03.2025 19min

Roisin McGuigan, Commissioning Editor, Nucleic Acid Insights, speaks to Stanley Crooke, Chairman, Founder and CEO, n-Lorem, about his long career and pioneering role in the antisense oligonucleotide (ASO) space, how RNA-targeting therapies are set to enter the mainstream, and his latest focus: making personalized, free-for-life ASO therapies available to nano-rare patient populations.

Exploring challenges, opportunities and state-of-the-art tools in the lipid nanoparticle space 19.02.2025 15min

Róisin McGuigan, Commissioning Editor, Nucleic Acid Insights, speaks to Ketaki Deshmukh, Senior Scientist, Novo Nordisk, about advanced characterization tools for LNPs, challenges in extrahepatic delivery, scalability issues, and the potential impact of AI and machine learning (ML) on future LNP development.

Driving innovation in cell and gene therapy: the role of AI and robotics 27.01.2025 15min

Jokūbas Leikauskas, Editor, Cell & Gene Therapy Insights, speaks with OmniaBio Inc.’s Kenneth Harris, Chief Strategy Officer and Head of AI, Mitchel Sivilotti, President and CEO, and Anthony Rotunno, Senior Vice President and General Manager/Site Head, about the innovative advancements in cell and gene therapy, focusing on how AI, automation, and robotics are revolutionizing manufacturing processes by reducing costs, increasing production capacity, and ultimately, improving patient outcom...

Spatial mapping: shaping the future of I-O diagnostics and treatment 06.12.2024 38min

Lauren Coyle, Commissioning Editor, Immuno-Oncology Insights, speaks with Banafshé Larijani, Director of the Centre for Therapeutic Innovation, University of Bath, about the development and application of a novel spatial mapping technology designed to improve cancer diagnostics and personalize treatment planning.

Pioneering quality control in biomanufacturing of cell and gene therapies 05.12.2024 28min

Lauren Coyle, Commissioning Editor, speaks with Dhruv Sareen, Executive Director at Cedars-Sinai Biomanufacturing Center, and Johnathan Rodriguez, Quality Control Manager at Cedars-Sinai Biomanufacturing Center, about the roles of in-process controls, method validation, risk management, and automation in biomanufacturing. They will highlight strategies to ensure product safety, consistency, and regulatory compliance for cell and gene therapy products.

Preparing for tomorrow’s cell and gene therapies today: lessons from 30 years in the field 06.09.2024 25min

For the first time in history, cell and gene therapy products are reaching the market in waves rather than in one’s and two’s, creating unprecedented challenges for pharma/biotech and healthcare sector stakeholders alike. David McCall, Senior Editor, BioInsights, speaks to Eric Faulkner, President and Chief Strategist, Passage Health Associates, about the chequered history of market access in the advanced therapies field, and what lessons can be taken forward to ensure a successful and sustai...

Insights into advanced therapies in the context of evolving funding and M&A environments 14.06.2024 22min

David McCall, Senior Editor, BioInsights, spoke to Lee Brown, Healthcare Sector Global Team Leader, Third Bridge Group, on Tuesday, February 6, 2024 to gain his insights into the fast-moving market landscape of advanced therapies. The discussion outlines key recent news and strategic moves from prominent pharma and biotech companies in the field, as well as the prospects for specific technologies such as CRISPR-based genome editing and next-generation CAR-T therapies.

Fit for function: developing potency assays reflective of the in vivo environment 10.05.2024 28min

Translating the therapeutic promise of cell and gene therapies into clinical reality relies on robust potency assays. However, designing assays that accurately reflect the complex mechanisms of these therapies can feel like chasing a moving target. Here, Charlotte Barker, Editor, Cell & Gene Therapy Insights, speaks with Giorgio Zenere, CMC technical project lead in the Global QC Technology Innovation Team, Kite Pharma, and Dirk Windgassen, Director of Analytical Development, Miltenyi Bio...

Gene therapy is having a monumental year: how can the industry keep up with supply? 04.04.2024 23min

Lauren Coyle, Commissioning Editor, Cell & Gene Therapy Insights, talks with Suman Subramanian, Head of Commercial Operations, Catalent Cell and Gene Therapy, to discuss the major achievements in the gene therapy market in 2023, with a focus on reliable manufacturing processes and strategies to enhance predictability while reducing waste in gene therapy manufacturing.

A deep dive in to generative AI applications in I-O 18.03.2024 43min

Lauren Coyle, Commissioning Editor, Immuno-Oncology Insights, speaks with André Freitas, Senior Lecturer (University of Manchester) and Research Group Leader (Idiap Research Institute/National Biomarker Centre), about the intersection of generative AI and experimental cancer treatments, with a focus on clinical trials, regulatory considerations, and leveraging emerging technologies for a transformative impact in I-O.